As Vaccines Roll Out, Americans See COVID-19 Testing as Important Partner

- The development and authorization of a COVID-19 vaccine is a critical scientific milestone in our efforts to combat this pandemic. Abbott (NYSE: ABT) released findings today from a survey conducted by The Harris Poll, showing that Americans see testing as an essential partner to these new vaccines. Among the key findings:

  • Importance of Testing as Partner to Vaccine: 82% of Americans say the
    COVID-19 vaccine rollout will be more effective if it works in partnership with testing.
  • Precautionary Measures Support Vaccines: When asked whether a vaccine by itself or a layered strategy would help combat the pandemic and allow us to get back to normal as quickly as possible, 73% of Americans believe a COVID-19 vaccine cannot succeed without other precautionary measures . However, when asked about concerns following approval of a vaccine, many are concerned (very or somewhat) that testing (71%), mask wearing (75%), and social distancing (76%) will decline following vaccine authorization.

"Like the rest of the globe, Americans are anxious to return to normalcy. The authorization of vaccines is an important and tremendous development in our fight against COVID-19," said Andrea Wainer, executive vice president, Rapid and Molecular Diagnostics, Abbott. "Americans agree that we should stay vigilant in other important safety measures, including testing, mask wearing and social distancing. Abbott will remain focused on providing as many tests as possible so people can access them throughout the duration of the pandemic and beyond."

Since the onset of the pandemic, Abbott has launched eight COVID-19 tests for emergency use in the U.S. including lab-based and rapid molecular tests, antibody tests, and a rapid antigen test, which was recently authorized for at-home use with a prescription and certified virtual guide. Abbott has delivered more than 300 million COVID-19 tests worldwide.

As we await widespread access to the vaccine, Americans agree that testing remains essential to curbing the pandemic right now.

  • Role of Testing in Interim: 86% of Americans say testing will play a significant (very or somewhat) role in combatting the pandemic while we wait for vaccines to be made widely available.
  • Importance of Detecting Infectiousness: 66% of Americans say rapid antigen COVID-19 testing is a critical tool to combat the pandemic because of its ability to detect the most infectious people.

As initial doses of the vaccines are prioritized for populations like frontline healthcare workers and seniors in long-term care facilities, rapid antigen tests are as important as ever to identify infectious individuals and slow the spread of the virus among those who have not been vaccinated.

"With cases rising and critical winter months ahead, we must continue to use every preventative measure available to us to slow the spread of the virus," said Mary Rodgers , PhD., principal scientist, Diagnostics, Abbott. "It's important that diagnostic companies, public health leaders, policymakers and citizens continue to advocate for the role of vaccines and testing in partnership with other important safety measures like mask wearing, social distancing and hand washing."

This survey was conducted online within the United States by The Harris Poll on behalf of Abbott from December 10 December 14, 2020 , among 2,064 U.S. adults ages 18 and older.

For a summary of the data, please click here .

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Cision View original content: https://www.prnewswire.com/news-releases/as-vaccines-roll-out-americans-see-covid-19-testing-as-important-partner-301197237.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% ww), is now available to patients through BC PharmaCare, the public drug program of British Columbia

ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

Keep reading...Show less

Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
{{ sections }}

Latest Press Releases

Related News

×